A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma

A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma - A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029991

Enrollment

Registered

2017-11-20

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

combination immunotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: resectable HCC

Exclusion criteria

Exclusion criteria: Uncontroled general complication. etc

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
1)specific CTL response in PBMC 2)specific CTL response in the tumor 3)relapse-free survival 4)overall survival	—

Countries

Japan

Contacts

Public ContactShoichi Hazama

Yamaguchi University School of Medicine Department of Translational Research and Developmental Therapeutics against Cancer

s.hazama@hcsdojinkai.or.jp0836-22-3186

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026